Medical Firm Reports Over 3,000% Surge in 2025 Net Profit Amid Industry-Wide Growth

　　【Pharmaceutical Network Industry Dynamics】In the past two days, several medical industry companies, including Maide Medical, Vishee Medical, SINOMED, CareChoice Medical, and United Imaging, have released their 2025 earnings reports. Among them, SINOMED and Maide Medical achieved a doubling of their performance.
 

According to the earnings快报 released by SINOMED on February 25, in 2025 the company achieved a total operating revenue of 525.4079 million yuan, an increase of 14.53% year-on-year; the net profit attributable to the parent company's owners was 47.2863 million yuan, an increase of 3,057.05% year-on-year. On February 26, VISHEE announced that in the 2025 fiscal year, the company achieved operating revenue of 447.419 million yuan, an increase of 62.79% year-on-year; the net profit attributable to the parent company's owners was 65.2599 million yuan, an increase of 426.61% year-on-year, turning losses into profits.
 

Regarding the growth in performance, SINOMED stated that the net profit attributable to the parent company's owners increased significantly year-over-year during this reporting period. This was mainly due to the continuous growth in operating revenue, with only a slight increase in operating costs and management expenses, while sales expenses, R&D expenses, and asset impairment losses decreased year-over-year. Additionally, the relatively low base of net profit attributable to the parent company's owners in the same period last year also contributed to this period’s significant increase. Despite a substantial year-over-year decline in investment income and a notable rise in income tax expenses, the net profit attributable to the parent company's owners still achieved significant year-over-year growth. Meanwhile, VISHEE stated that the performance growth was primarily driven by the company’s coordinated production efforts and commitment to innovation, with strong development in blood purification and pharmaceutical-device combination intelligent equipment businesses, leading to a substantial increase in revenue from pharmaceutical-device combination intelligent equipment.
 

In addition, VISHEE and United Imaging achieved double growth in revenue and profit in 2025. According to the earnings快报 released by United Imaging on February 25, in 2025, the company achieved operating revenue of 13.821 billion yuan, a year-on-year increase of 34.18%; net profit attributable to shareholders of 1.888 billion yuan, a year-on-year increase of 49.60%. According to the earnings快报 released by VISHEE on February 26, in the fiscal year 2025, the company achieved total operating revenue of 462.7257 million yuan, an increase of 15.66% year-on-year; net profit attributable to the parent company's owners was 136.632 million yuan, an increase of 33.99% year-on-year.
 

Regarding the performance growth, United Imaging stated that during the reporting period, the company systematically advanced the introduction of innovative products, deepened the global market layout, optimized the supply chain system, and accumulated core technical capabilities. Against the backdrop of China's large-scale medical equipment renewal policy entering a normalized and specialized implementation phase by 2025, the demand for high-end medical imaging, radiotherapy, and equipment related to primary healthcare capacity building continued to be released, leading to a significant recovery in the overall industry scale compared with the same period last year. The company continuously enhanced and maintained its position in the domestic market, achieving substantial growth in revenue from the Chinese market, with simultaneous improvements in operational quality and profitability.
 

The Remarkable Performance of Multiple Medical Enterprises Reflects the Trend of High-Quality Development in China's Medical Industry. In recent years, the state has introduced a series of policies to form a combination punch to protect the development of the medical industry. From the enterprise level, whether it is SINOMED's cost control, VISHEE's business innovation, or United Imaging's technological progress, it reflects the continuous efforts of medical enterprises in refined operation and core competitiveness cultivation.
 

The 2025 earnings快报 disclosed by multiple medical companies fully demonstrate the strong resilience and development potential of China's medical industry. Driven by policy empowerment, technological innovation, and market demand, medical companies continue to optimize their business structures, enhance core competitiveness, and promote industry transformation.
 

Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.